Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity

Catalysts

About Vaxcyte

Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use.

What are the underlying business or industry changes driving this perspective?

• Multiple ongoing late stage VAX-31 adult trials and the planned BLA package are aligned with existing FDA frameworks for pneumococcal vaccines. If successful, these programs could support future product approvals and create a path to commercial revenue.
• Expanded adult pneumococcal vaccination recommendations in the US and increasing adoption of adult PCV programs internationally are enlarging the addressable market for higher valency vaccines such as VAX-31. This directly relates to potential future revenue scale.
• VAX-31 aims to cover more serotypes than current adult standards of care. Regulators assess products on the totality of public health impact, which, if reflected in future guidelines and usage, could influence long-term revenue and market share and support operating leverage on fixed costs.
• Completion of a dedicated large-scale manufacturing facility and progress on a high-volume fill-finish line are intended to support global supply for PCV candidates. This can be important for serving broader demand and improving unit economics and margins over time.
• Resumption of development for VAX-A1, targeting Group A Strep in both adults and children, positions the company in another large infectious disease area where current burden and costs are high. This could diversify future revenue streams and spread R&D and commercial infrastructure across more than one product.
• A cash, cash equivalents and investments balance of about US$3.0b and stated runway to at least the end of 2028 support continued investment in clinical programs, manufacturing readiness and commercialization activities without relying on near-term external funding. This can help manage earnings volatility during the pre-revenue phase.

Assumptions

How have these above catalysts been quantified?

• Vaxcyte currently has no revenue. Analysts are forecasting revenue to reach $224.6 million by March 2029.
• Analysts are not forecasting that Vaxcyte will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Vaxcyte's profit margin will increase from 0.0% to the average US Biotechs industry of 12.5% in 3 years.
• If Vaxcyte's profit margin were to converge on the industry average, you could expect earnings to reach $28.1 million (and earnings per share of $0.16) by about March 2029, up from -$766.6 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 840.4x on those 2029 earnings, up from -10.2x today. This future PE is greater than the current PE for the US Biotechs industry at 16.2x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.09%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Vaxcyte is still a pre revenue company and management expects R&D and manufacturing expenses to rise meaningfully as multiple late stage trials and commercial scale production ramp. If costs grow faster than expected or timelines extend, cash could be consumed more quickly than the current runway guidance to at least the end of 2028, putting pressure on future financing needs, net margins and earnings.
• The investment case leans heavily on OPUS-1, OPUS-2, OPUS-3 and infant VAX-31 data leading to approvals and broad use in adults and children, yet management repeatedly acknowledges that perfection on serotype responses is not required and regulators assess the totality of data. If key serotypes underperform, catch up recommendations are weaker than hoped or ACIP and international bodies prefer existing options, potential revenue and operating leverage could fall short of expectations.
• Current commentary highlights growing adult PCV use in the US, new age group recommendations and increasing international adoption, but this demand depends on continued supportive vaccine policy, payer coverage and public health priorities. If future guideline changes slow adoption, reduce eligible age groups or favor competing products, that could limit the long term addressable market and constrain revenue growth and earnings.
• Vaxcyte is investing up to US$1b in US manufacturing and has completed a large scale facility with Lonza alongside a custom fill finish line. However, complex biologics manufacturing carries execution, quality and regulatory inspection risk, so any delay, cost overrun, batch failure or post marketing safety signal that leads to remediation work could weigh on gross margins, cash usage and earnings.
• The thesis assumes VAX-31 can set a new standard relative to Prevnar 20 and Capvaxive and that VAX-A1 can evolve into a significant Group A Strep product, but large incumbents like Pfizer, Merck, GSK and Sanofi are all active in PCVs and pediatric vaccines, and rivals are already gaining share based on higher serotype coverage. More aggressive competition, faster rival product cycles or future higher valency PCVs from others could cap Vaxcyte’s pricing power, compress long run net margins and limit earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $109.0 for Vaxcyte based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $163.0, and the most bearish reporting a price target of just $67.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $224.6 million, earnings will come to $28.1 million, and it would be trading on a PE ratio of 840.4x, assuming you use a discount rate of 7.1%.
• Given the current share price of $54.28, the analyst price target of $109.0 is 50.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.